A potential single-infusion treatment from Bristol Myers Squibb met key trial goals in myeloma.
Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated patient population who have been exposed to a prior BCMA-targeted therapy
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Multiple Myeloma Clinical Trials & Emerging Therapies
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy